Evidence map›Paper›PMID 41652151›Full record

ArticleMolecular psychiatry2026

UBE3A isoform-selective and non-selective contributions to Angelman syndrome phenotypes.

Joseph C Krzeski, Edwin J Mientjes, Matthew C Judson, Guangkuo Dong, Rebecca I Hipp, Katelyn H Lien, Bin Gu, Benjamin D Philpot, Ype Elgersma

Abstract read
In one paragraph

Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Joseph C Krzeski *Department of Cell Biology & Physiology, University of North Carolina, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0003-1116-7482
Edwin J Mientjes *Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-6700-9259
Matthew C JudsonDepartment of Cell Biology & Physiology, University of North Carolina, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-8659-1654
Guangkuo DongDepartment of Cell Biology & Physiology, University of North Carolina, Chapel Hill, NC, USA.
Rebecca I HippDepartment of Cell Biology & Physiology, University of North Carolina, Chapel Hill, NC, USA.ORCID http://orcid.org/0009-0008-2819-4405
Katelyn H LienDepartment of Cell Biology & Physiology, University of North Carolina, Chapel Hill, NC, USA.
Bin GuDepartment of Neuroscience, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-6846-5563
Benjamin D PhilpotDepartment of Cell Biology & Physiology, University of North Carolina, Chapel Hill, NC, USA. bphilpot@med.unc.edu.ORCID http://orcid.org/0000-0003-2746-9143
Ype ElgersmaDepartment of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands. y.elgersma@erasmusmc.nl.ORCID http://orcid.org/0000-0002-3758-1297

Funding

Preclinical CoreP50HD103573 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark D Shen · 2020 to 2026
$9.7M
UBE3A gain-of-function and parent-of-origin influence on neurodevelopmental phenotypesR01MH120229 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PHILPOT, BENJAMIN D, ZYLKA, MARK J. · 2019 to 2023
$3.4M
Small Molecule Therapeutic Discovery for Angelman SyndromeR01NS131615 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jeffrey Aube, BENJAMIN D PHILPOT · 2023 to 2026
$2.3M
TCF4 in Pitt-Hopkins syndromeR01NS114086 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PHILPOT, BENJAMIN D · 2019 to 2023
$1.7M
Investigating UBE3A as a driver gene in Duplication 15q syndromeR01NS129914 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENJAMIN D PHILPOT · 2023 to 2026
$1.6M
Causally linking UBE3A misexpression to altered circuit dynamics controlling skilled movementsR01NS145518 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Adam Hantman, Matthew Charles Judson · 2025 to 2026
$1.2M
The Role of UBE3A Isoforms in AS-associated Seizure SusceptibilityF31NS139445 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph Krzeski · 2024 to 2026
$122k
NICHD NIH HHS P50 HD103573NIMH NIH HHS R01 MH120229NINDS NIH HHS F31 NS139445NINDS NIH HHS R01 NS114086NINDS NIH HHS R01 NS129914NINDS NIH HHS R01 NS131615NINDS NIH HHS R01 NS145518Simons Foundation 702556U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01MH120229U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) F31NS139445U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS114086U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS129914U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS131615U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01NS145518
6 · The paper itself

Abstract

Angelman syndrome (AS) is a neurodevelopmental disorder caused by UBE3A loss. In humans, UBE3A generates three isoforms that localize to distinct subcellular compartments-one mainly nuclear and two cytoplasmic. The nuclear and most highly expressed cytoplasmic UBE3A isoform are highly conserved in mice, whereas the cytoplasmic human isoform accounting for just ~1% of total UBE3A has no mouse counterpart. Loss of the nuclear-enriched UBE3A isoform causes AS and behavioral deficits in mice; no specific contribution of the predominant cytoplasmic UBE3A isoform has yet been identified. Because the nuclear-enriched isoform constitutes ~80% of total UBE3A protein, it is unclear if its outsized phenotypic impact upon deletion is due to a loss of nuclear UBE3A function or simply a dramatic reduction in overall UBE3A levels. If the former, overexpression of the cytoplasmic UBE3A isoform would be unable to rescue AS phenotypes. To test this, we developed a mouse model that overexpresses the cytoplasmic UBE3A isoform (mIso2-OE) and crossed it with an AS mouse model to yield wildtype (WT), mIso2-OE, AS, and AS/mIso2-OE mice, the latter of which lacked the endogenous nuclear UBE3A isoform (mIso3) in neurons. Unexpectedly, we found that overexpression of the cytoplasmic UBE3A isoform alone rescued most tested AS-related behavioral deficits, except for kindling-induced epileptogenesis or seizure-linked perineuronal net (PNN) accumulation in AS mice. Thus, while many AS phenotypes may be caused by isoform non-selective reductions in UBE3A levels, AS-associated epilepsies appear linked to isoform-selective nuclear UBE3A loss. This information is expected to inform AS gene therapy studies.

Indexed as

Angelman SyndromeUbiquitin-Protein LigasesAnimalsBrainCytoplasmDisease Models, AnimalFemaleHumansMaleMiceNeuronsPhenotypeProtein IsoformsProtein IsoformsUbe3a protein, mouseUbiquitin-Protein Ligases

Identifiers

PMID41652151
PMCPMC13190305

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.